Additional Benefit of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric Rhabdomyosarcoma

Ricard, Fabien; Cimarelli, Sébastien; Deshayes, Emmanuel; Mognetti, Thomas; Thiesse, Philippe; Giammarile, Francesco

doi:10.1097/rlu.0b013e318217ae2e

Cited by 74 publications

(43 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For staging purposes, the results of a prospective multicenter trial of 46 pediatric and adolescent patients indicated a marked added value of 18 F-FDG PET over conventional imaging for the detection of additional lesions and a relevant impact on therapy planning (40). Ricard et al (43) evaluated the additional benefit of 18 F-FDG PET/CT for staging and follow-up in 13 pediatric patients with rhabdomyosarcoma; they concluded that 18 F-FDG PET/CT was useful, especially for assessing lymph node and bone involvement and for cases in which the primary sites of rhabdomyosarcoma were unclear. By analogy, whole-body PET/MR may have great potential to become an integrated part of the diagnostic algorithm in the future (15).…”

Section: Soft-tissue Tumorsmentioning

confidence: 99%

Potential Pediatric Applications of PET/MR

et al. 2014

View full text Add to dashboard Cite

Medical imaging with multimodality and whole-body technologies has continuously improved in recent years. The advent of combined modalities such as PET/CT and PET/MR offers new tools with an exact fusion of molecular imaging and high-resolution anatomic imaging. For noninvasive pediatric diagnostics, molecular imaging and whole-body MR have become important, especially in pediatric oncology. Because it has a lower radiation exposure than PET/CT, combined PET/MR is expected to be of special use in pediatric diagnostics. This review focuses on possible pediatric applications of PET/MR hybrid imaging, particularly pediatric oncology and neurology but also the diagnosis of infectious or inflammatory diseases.

show abstract

Section: Soft-tissue Tumorsmentioning

confidence: 99%

Potential Pediatric Applications of PET/MR

et al. 2014

View full text Add to dashboard Cite

show abstract

“…It was recommended that bone scans be omitted if bone sarcomas are evaluated with 18 F-FDG PET (81). The appropriateness of this recommendation was confirmed by studies that evaluated rhabdomyosarcomas and bone sarcomas separately: for detection of bone metastases in rhabdomyosarcomas, 18 F-FDG PET/CT showed a sensitivity of 100%, compared with 66% for conventional imaging modalities, including radiography, CT, MR imaging (79), or bone scintigraphy alone (2,71). For detection of bone metastases in Ewing sarcomas, 18 F-FDG PET showed a sensitivity of 88%, compared with 37% for conventional imaging modalities (78).…”

Section: Initial Stagingmentioning

confidence: 85%

“…Several studies have demonstrated improved sensitivities and specificities for 18 F-FDG PET/CT compared with all collective standard staging procedures, specifically for patients with lymphomas, sarcomas, and head and neck cancers (1)(2)(3)(4). However, exposure of children to radiation through 18 F-FDG PET/CT is of concern to the pediatric imaging community (5,6), and various low-dose approaches are being pursued (7)(8)(9).…”

mentioning

confidence: 99%

Value of¹⁸F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies

et al. 2015

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) understand the current status of the role of 18 F-FDG PET and PET/CT for staging and treatment monitoring of pediatric malignancies; (2) discuss the limitations of 18 F-FDG PET and PET/CT for pediatric cancer imaging; and (3) discuss areas of pediatric cancer imaging in which further studies are needed.

show abstract

“…A recent prospective comparative study on soft-tissue sarcoma staging reported that 18 F-FDG PET is superior to conventional diagnostic imaging techniques (MRI of the tumor primary site, whole-body CT, and 99m Tc-methyl diphosphonate bone scintigraphy) for N-staging, with a sensitivity of 95% versus 25%, respectively (26). 18 F-FDG PET/CT was reported to change the N-stage in 4 of 13 rhabdomyosarcoma patients in a smaller series (21). Interestingly, a retrospective study on PET with the radiotracer 11 C-choline reported 100% accuracy for N-staging in softtissue sarcomas and an overall accuracy of 94% for TNM staging, versus 50% for conventional imaging modalities (27).…”

Section: Soft-tissue Sarcomamentioning

confidence: 99%

“…The availability of additional PET data will not obviate definite histopathologic diagnosis by biopsy; thus, PET/MRI is not expected to be of additional use in the primary diagnosis of undetermined softtissue masses. But analogously to 18 F-FDG PET, there might be an indication for integrated whole-body PET/MRI in the diagnostic algorithm in cases of sarcoma in which the primary location is unknown (21).…”

Section: Soft-tissue Sarcomamentioning

confidence: 99%

Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma

Buchbender

Heusner²,

Lauenstein³

et al. 2012

J Nucl Med

151

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the advantages and disadvantages of PET/MRI in oncologic applications in comparison to conventional imaging methods and PET/CT; (2) the limitations of PET/MRI compared with invasive staging procedures (biopsy); and (3) the metabolic-anatomic imaging procedure of choice (PET/MRI vs. PET/CT) based on tumor entity and location.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through August 2013.With integrated whole-body PET/MRI, a novel metabolicanatomic imaging technique recently has been introduced into clinical practice. This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. If PET/ MRI literature is not yet available for some types of tumors, potential indications are based on available PET/CT and MRI data. PET/MRI seems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas. With regard to N-staging, PET/MRI can be considered similarly accurate to PET/CT when applied as a whole-body staging approach. M-staging will benefit from MRI accuracy in the brain, the liver, and bone. Imagi ng plays a key role in diagnosis and staging in oncology. Evaluation of local tumor extent and detection of potential locoregional lymph node or distant metastases according to the periodically revised standardized TNM cancer staging system (1) directly affects patient care by defining the most suitable therapy. With integrated wholebody PET/MRI, a new metabolic-anatomic imaging modality has been introduced into clinical practice. Despite the fact that the solution of basic problems, such as adequate MRI-based attenuation correction, is still a work in progress (2), reports on initial clinical experiences with PET/MRI in oncology are already available. In this second part of our review on PET/MRI in oncologic applications, we summarize the available first experiences with PET/ MRI in bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. In fields where PET/MRI data are lacking, we outline the potential role of PET/MRI on the basis of the PET/CT and MRI literature. To provide further information on PET/MRI, we refer to our own unpublished experiences with PET

show abstract

Additional Benefit of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric Rhabdomyosarcoma

Abstract: FDG PET/CT can be useful in staging and restaging pediatric RMS, especially for assessing lymph nodes and bone involvement, and for detecting unknown primary sites of RMS, with potential therapeutic strategy alteration.

Cited by 74 publications

References 28 publications

Potential Pediatric Applications of PET/MR

Potential Pediatric Applications of PET/MR

Value of¹⁸F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies

Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma

Contact Info

Product

Resources

About

Additional Benefit of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric Rhabdomyosarcoma

Abstract: FDG PET/CT can be useful in staging and restaging pediatric RMS, especially for assessing lymph nodes and bone involvement, and for detecting unknown primary sites of RMS, with potential therapeutic strategy alteration.

Cited by 74 publications

References 28 publications

Potential Pediatric Applications of PET/MR

Potential Pediatric Applications of PET/MR

Value of18F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies

Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma

Contact Info

Product

Resources

About

Value of¹⁸F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies